Trial funded by Patient-Centered Outcomes Research Institute aims to
compare the benefits and risks for two commonly used doses of aspirin in
people with heart disease
INDIANAPOLIS--(BUSINESS WIRE)--Nov. 8, 2017--
Anthem Inc. is committed to playing an active role in identifying best
approaches to health and care management. As part of that belief,
Anthem’s outcomes research subsidiary, HealthCore Inc., will begin
reaching out to select members of Anthem affiliated health plans
regarding an opportunity to participate in an innovative research study
on heart disease. The study is currently underway to help determine the
most effective and safest dose of aspirin to prevent heart attacks and
strokes, and Anthem’s affiliated health plans are expected to play a
significant role in recruitment.
This landmark study, called ADAPTABLE, involves more than 30 leading
health and medical organizations across the U.S. with a goal of
enrolling 15,000 participants. The study, which is funded by the
Patient-Centered Outcomes Research Institute (PCORI), will compare
regular strength aspirin (325mg) to “baby” aspirin (81mg) among people
with heart disease to help determine the best dose to use. While aspirin
is widely prescribed to prevent strokes and heart attacks in people
living with heart disease, the right dose is not established. This is
because one dose may be better at preventing heart attacks while another
may prevent serious side effects, such as bleeding.
Heart disease causes one in four deaths in the U.S., making it the
country’s leading killer, and heart disease places enormous burdens on
patients and their families as well as the U.S. healthcare system. While
the ADAPTABLE trial is important on its own, it’s also the first study
to be conducted through PCORnet, the National Patient-Centered Clinical
Research Network. This innovative PCORI initiative is designed to
empower people to make informed healthcare decisions by enabling
clinical research that is faster, easier, less costly and, most
importantly — more relevant to their needs.
“HealthCore and Anthem are excited to be taking part in this important
trial, which is expected to yield practical, real-world guidance for the
more than 15.4 million Americans living with heart disease,” said Mark
Cziraky, HealthCore Vice President of Research and ADAPTABLE site
primary investigator. “We’re taking the outreach for this trial to
members who live across the country, and many are in rural or other
geographies that aren’t reached by traditional clinical trials.”
The ADAPTABLE study is one of several real-world comparative
effectiveness research projects HealthCore is working on as part of a
funding award received last year from PCORI.
“We hope that what we learn from ADAPTABLE will improve the care and
outcomes for patients with heart disease,” said Adrian Hernandez, MD,
MHS, ADAPTABLE Co-Principal Investigator. “But we are also excited by
the prospect that this study will be a pragmatic model of leveraging
data from multiple sources to help answer many other health questions
that patients and their doctors face every day.”
Anthem health plan-contracted physicians should receive letters within
the next few weeks, advising them that Anthem will be sending
information about this study to members who meet the study criteria. The
letters will advise the selected Commercial, Medicare Advantage and
Medicare Supplemental members to consult their doctor with any questions
related to their ability to participate, as their enrollment may
randomize them to a new aspirin dose.
Researchers will follow each participant for 30 months and look at the
overall benefits and side effects of the various aspirin doses by
gender, age, ethnicity and race as well as in patients with medical
conditions in addition to heart disease, such as diabetes. The data will
be collected electronically, reducing the burden on participants who
won’t need to return to the clinic for numerous study visits. More
information on the ADAPTABLE study can be found at theaspirinstudy.org.
PCORnet, the National Patient-Centered Clinical Research Network, is an
innovative initiative of the Patient-Centered Outcomes Research
Institute (PCORI). The goal of PCORnet is to improve the nation’s
capacity to conduct clinical research by creating a large, highly
representative network that directly involves patients in the
development and execution of research. More information is available at www.pcornet.org.
PCORI is an independent, nonprofit organization authorized by Congress
in 2010. Its mission is to fund research that will provide patients,
their caregivers, and clinicians with the evidence-based information
needed to make better-informed healthcare decisions. For more
information about PCORI’s funding, visit www.pcori.org.
About HealthCore Inc.
HealthCore Inc., www.healthcore.com,
uses real world data, including claims information, to provide clinical
and other scientific expertise and research services to the
pharmaceutical, biotechnology and device industries, in the conduct of
industry-sponsored safety, health economic outcomes, comparative
effectiveness, epidemiological and late stage research projects.
HealthCore’s capabilities include retrospective database design and
analysis, prospective observational research design and analysis, safety
and epidemiologic research services, post authorization safety study
(PASS), health services research, patient and/or provider survey
development and implementation, and general research consultation.
About Anthem, Inc.
Anthem is working to transform health care with trusted and caring
solutions. Our health plan companies deliver quality products and
services that give their members access to the care they need. With over
73 million people served by its affiliated companies, including more
than 40 million within its family of health plans, Anthem is one of the
nation’s leading health benefits companies. For more information about
Anthem’s family of companies, please visit www.antheminc.com/companies.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171108006225/en/
Source: Anthem Inc.